Adverse effect · Selank

How common is safety in humans with Selank?

D
Grade D — no human evidenceNo systematic international data · effect size: not measurable · adverse
Short answerNo human evidence. As of 2 September 2026, only no systematic international data exist for Selank for safety in humans. Reported as well tolerated in Russian use; no modern pharmacovigilance dataset.

What the studies show

Reported as well tolerated in Russian use; no modern pharmacovigilance dataset.

Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.

In context

Selank is a synthetic analogue of tuftsin, an immune-signalling peptide, developed in Russia alongside Semax and registered there as an anxiolytic. Small Russian studies report anxiety reduction comparable to benzodiazepines without sedation; none has been replicated internationally or published to standards that allow the claim to be checked. It is not approved in the EU, US or UK.

Selank is not approved (outside russia). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Selank proven to cause safety in humans?
No. There is no human evidence for it (No systematic international data); the claim rests on animal or cell studies and LYO grades it D.
What studies are behind the grade?
Reported as well tolerated in Russian use; no modern pharmacovigilance dataset.
Is Selank approved for this?
No. Selank is not approved (outside Russia); it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for Selank

Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →